Key points are not available for this paper at this time.
TAFRO syndrome is an acute systemic inflammatory disorder characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. While its lymph node pathology is similar to that of idiopathic multicentric Castleman disease (iMCD), the clinical features of TAFRO syndrome differ from those of typical iMCD, as they include a more aggressive clinical course and high mortality. However, an optimal treatment strategy for TAFRO syndrome has not yet been established, owing to a poor understanding of its pathogenesis. The limited cases we encountered suggest that tacrolimus treatment in combination with glucocorticoids may potentially be effective and well tolerated as an initial treatment, and hold promise as a glucocorticoid-sparing agent. Herein, we report an additional case and review the sparse literature available regarding TAFRO syndrome treated via tacrolimus.
Building similarity graph...
Analyzing shared references across papers
Loading...
Taiichiro Shirai
Immune Regulation (United Kingdom)
Shinya Ichikawa
Kobe University
Jun Saegusa
Kobe University Hospital
Biomedicines
The University of Osaka
Kobe University
Building similarity graph...
Analyzing shared references across papers
Loading...
Shirai et al. (Sun,) studied this question.
synapsesocial.com/papers/68e6a888b6db64358762b32d — DOI: https://doi.org/10.3390/biomedicines12051070
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: